Trially AI has built a fully integrated, HIPAA-compliant platform that tackles the biggest bottleneck in clinical research—patient recruitment. Its core products include Trially Match, which analyzes unstructured EHR data to find eligible participants; Trially Connect, where the new agentic AI assistant “Margo” engages and pre-screens those candidates; and Trially Intelligence, a pipeline radar that flags suitable trials for a given patient population. The system can identify patients with roughly 95% screening accuracy, enroll 2–6× more patients per month in complex trials, reduce screen failures by 73%, and cut manual chart-review time by 91%. One research site network reported a $4 million revenue increase within three months of deployment, and users see as much as a 10× jump in identified trial candidates. The company positions itself for physicians, research sites, CROs, and pharmaceutical sponsors needing faster, more diverse enrollment. With fresh seed funding, management plans to accelerate platform adoption across research sites, sponsors, CROs, and physician networks. Financially, Trially AI has secured $4.7 million in seed capital to fuel this next phase of growth.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2025